Novartis CEO on Platform-Driven Transformation
On the a16z Show, Novartis CEO Vasant Narasimhan explained how the company transformed by focusing on core platform technologies like cell and gene therapies. By spinning off non-core businesses, the company unlocked $180 billion in value. This strategy provides a model for vertical AI startups on how to build competitive moats by solving deep, industry-specific problems rather than offering general-purpose automation.
- The two largest divestitures were the 2019 spin-off of the Alcon eye care business, valued at nearly $29 billion, and the 2023 spin-off of Sandoz, its generics and biosimilars division, which created Europe's largest generics company. - The company's strategy focuses on five core technology platforms: two established ones (chemistry and biotherapeutics) and three next-generation platforms (xRNA, radioligand therapy, and cell & gene therapy). - This strategic shift is part of CEO Vasant Narasimhan's plan to create a "pure-play" innovative medicines company, concentrating investment in five therapeutic areas: cardiovascular, immunology, neuroscience, solid tumors, and hematology. - The transformation involved over $100 billion in transactions, enabling Novartis to focus its capital and management attention entirely on innovative medicines. - To accelerate research and development, Novartis partnered with AWS and Accenture to build a "next-generation data platform," applying AI and machine learning with the goal of reducing the typical 12-year drug development timeline. - As part of its new focus, Novartis is implementing a "U.S.-first" mindset, aiming to become a top-five pharmaceutical company in the U.S. by 2027 and is investing a planned $23 billion in American manufacturing and R&D infrastructure over five years.
